|
Rubinsky’s cancer treatment demonstrated |
April 24, 2008
A cancer treatment developed by BioE and Mechanical Engineering Professor Boris Rubinsky underwent its first human clinical trial this month.
The licensing company AngioDynamics reported that the first human clinical use employing irreversible electroporation (IRE) to ablate soft tissue was completely successful based on analysis of biopsies performed on five patients two weeks after their treatment.
IRE is a non-thermal tissue ablation technique in which electrical fields are used to create nanoscale defects in a cell's membrane, which causes cell death only in the targeted tissue. It does not destroy critical structures such as ducts, blood vessels and nerves.
To read the full articles, visit the Street Insider. |
